The Institute of Medicine conducted a study on the current status of, and future opportunities to improve, cardiac arrest treatment and outcomes in the United States. This report examines the complete system of response to cardiac arrest in the United …
The Institute of Medicine (IOM) report Crossing the Quality Chasm identified six fundamental aims for health care—that it be safe, effective, patient-centered, efficient, equitable, and timely. Of these fundamental aims, timeliness is in some ways the …
This joint workshop by the Institute of Medicine, the National Research Council, and Fundação Maria Cecilia Souto Vidigal was held in São Paulo, Brazil, on November 11, 2014, and focused on scaling program investments for young children globally.
This joint workshop by the Institute of Medicine, the National Research Council, and Fundação Maria Cecilia Souto Vidigal was held in São Paulo, Brazil, on November 11, 2014, and focused on scaling program investments for young children globally.
Biological differences between the sexes influence not only individual health but also public health, biomedical research, and health care. The IOM held a workshop March 8-9, 2010, to discuss sex differences and their implications for translational neu…
Millions of people in sub-Saharan Africa suffer from mental, neurological, and substance use (MNS) disorders, and most do not have the resources to obtain treatment. The Uganda National Academy of Sciences and the IOM hosted a workshop to discuss the s…
Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer’s, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The IOM’s Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers.
The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior. The IOM’s Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Biological differences between the sexes influence not only individual health but also public health, biomedical research, and health care. The IOM held a workshop March 8-9, 2010, to discuss sex differences and their implications for translational neu…
Millions of people in sub-Saharan Africa suffer from mental, neurological, and substance use (MNS) disorders, and most do not have the resources to obtain treatment. The Uganda National Academy of Sciences and the IOM hosted a workshop to discuss the s…
